Cross-Talk between F3/Contactin and Notch at Axoglial Interface: A Role in Oligodendrocyte Development

Hu, Qidong; Gennarini, Gianfranco; Xiao, Zhi‐Cheng

doi:10.1159/000090750

Cited by 49 publications

(45 citation statements)

References 121 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Q-RT-PCR results revealed five genes with significant differential expression (p .05; as determined by t-test) both between small and large prostate and by at least one of the drug treatments. These genes included three pro-inflammatory chemokines, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), which are all induced by interferon-γ (IFNγ) and act through the same G protein coupled receptor CXCR3 38,39 ; the Wnt signaling inhibitor, DKK3 40 , one of several Wnt genes identified in our analysis; and the predominantly neural adhesion molecule Contactin 1 41 , which has recently been shown to be involved in Notch signaling 42,43 . Contactin 1 is of particular interest since its adhesion ligands CD56 and tenascin are expressed in prostate stroma 44,45 .…”

Section: Bph Biomarkers Arising From Microarray Analysis Of Enlarged mentioning

confidence: 91%

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

et al. 2008

View full text Add to dashboard Cite

Purpose-Clinical benign prostatic hyperplasia (BPH) is primarily diagnosed based on a diverse array of progressive lower urinary tract symptoms (LUTS) and is likely distinct from histological BPH, which is detected by the presence of non-malignant proliferation of prostate cells but may or may not be associated with symptoms. Pharmacological management of LUTS has emerged as an effective initial treatment for clinical BPH due to the introduction of new drug therapies shown to be effective in recent large clinical trials. Despite advances in symptom management and research into BPH pathology, diagnostic strategies for prediction of BPH progression and response to drug modalities are lacking and questions remain as to the molecular differences underlying clinical (symptomatic) versus histological (non-symptomatic) BPH. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Results-To date the MPSA has identified a number of promising biomarkers and other molecular and cellular changes associated with BPH. NIH Public AccessConclusions-These findings and ongoing consortium discovery efforts have the potential to provide a greater understanding of the defects underlying disease pathology and may lead to the development of early and more effective pharmacological treatment strategies for BPH.

show abstract

Section: Bph Biomarkers Arising From Microarray Analysis Of Enlarged mentioning

confidence: 91%

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

et al. 2008

View full text Add to dashboard Cite

show abstract

“…observations show that Notch regulatory processes encompass dissimilar mechanisms, such as chemical modifications, vesicular trafficking and interactions with other proteins (Haines & Irvine 2003, Le Borgne 2006, Hu et al 2006, Jaekel & Klein 2006. These studies have begun to paint a more elaborate picture and elucidate some of these regulatory pathways, as we shall describe in the next section.…”

Section: The Canonical Pathwaymentioning

confidence: 99%

Cell and molecular biology of Notch

Fiúza

Arias

2007

Journal of Endocrinology

317

288

View full text Add to dashboard Cite

Notch signalling is a cell-cell communication process, which allows the establishment of patterns of gene expression and differentiation, regulates binary cell fate choice and the maintenance of stem cell populations. So far, the data published has elucidated the main players in the Notch signalling pathway. However, its regulatory mechanisms are exhibiting an increasing complexity which could account for the multitude of roles it has during development and in adult organisms. In this review, we will describe the multiple roles of Notch and how various factors can regulate Notch signalling.

show abstract

“…Thus, by modulating the surface expression of Na v 1.2, contactin-1 may contribute to this compensatory mechanism. Other studies have also shown that contactin plays a role in axogenesis, oligodendrocyte development, and myelination [69][70][71].…”

Section: Proteomic Analysis Of the Csf Obtained From Multiple Sclerosmentioning

confidence: 96%

Proteomic strategies in multiple sclerosis and its animal models

Elkabes

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

The early and precise diagnosis, the prognosis, and the clinical management of multiple sclerosis, remain a considerable challenge. In recent years, the development of novel and powerful proteomic techniques prompted the use of these approaches for the search of unique biomarkers in the cerebrospinal fluid of multiple sclerosis patients. A few studies have also utilized proteomics to delineate the profile of differentially expressed proteins in animal models of the human disease in order to gain global insights into affected pathways. The identification of differentially expressed proteins may be an initial step in the discovery of novel targets and mechanisms that play critical roles in the pathology of multiple sclerosis. Based on these findings, future investigations may elucidate the events leading to demyelination, axonal damage, and neurodegeneration, providing better insights into mechanisms governing the onset and progression of the disease. Although these proteomic studies provide valuable information, they are also faced with a number of challenges. The present review discusses some of the strengths and limitations of proteomic investigations as applied to multiple sclerosis.

show abstract

Cross-Talk between F3/Contactin and Notch at Axoglial Interface: A Role in Oligodendrocyte Development

Cited by 49 publications

References 121 publications

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

Cell and molecular biology of Notch

Proteomic strategies in multiple sclerosis and its animal models

Contact Info

Product

Resources

About